• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.

作者信息

Sequist Lecia V, Piotrowska Zofia, Niederst Matthew J, Heist Rebecca S, Digumarthy Subba, Shaw Alice T, Engelman Jeffrey A

机构信息

Massachusetts General Hospital Cancer Center, Boston2Harvard Medical School, Boston, Massachusetts.

Harvard Medical School, Boston, Massachusetts3Department of Radiology, Massachusetts General Hospital, Boston.

出版信息

JAMA Oncol. 2016 Apr;2(4):541-3. doi: 10.1001/jamaoncol.2015.5009.

DOI:10.1001/jamaoncol.2015.5009
PMID:26720284
Abstract
摘要

相似文献

1
Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.在接受罗西替尼治疗的患者疾病进展后使用奥希替尼的疗效
JAMA Oncol. 2016 Apr;2(4):541-3. doi: 10.1001/jamaoncol.2015.5009.
2
Prolonged Partial Response to Osimertinib after Disease Progression to Rociletinib in Metastasic EGFR T790M-Positive Non-Small Cell Lung Cancer.
J Thorac Oncol. 2018 May;13(5):e77-e79. doi: 10.1016/j.jtho.2017.12.015.
3
Osimertinib efficacious as maintenance therapy in patients with stage III NSCLC.奥希替尼作为Ⅲ期非小细胞肺癌患者的维持治疗有效。
Nat Rev Clin Oncol. 2024 Aug;21(8):566. doi: 10.1038/s41571-024-00915-w.
4
Osimertinib improves progression-free survival in NSCLC.奥希替尼可改善非小细胞肺癌的无进展生存期。
Lancet Oncol. 2018 Jan;19(1):e10. doi: 10.1016/S1470-2045(17)30893-8. Epub 2017 Nov 23.
5
Osimertinib effective in EGFR T790M-positive lung cancer.奥希替尼对EGFR T790M阳性肺癌有效。
Lancet Oncol. 2017 Jan;18(1):e9. doi: 10.1016/S1470-2045(16)30654-4. Epub 2016 Dec 16.
6
Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.奥希替尼用于表皮生长因子受体（EGFR）T790M突变阳性的非小细胞肺癌
Expert Rev Clin Pharmacol. 2017 Jan;10(1):31-38. doi: 10.1080/17512433.2017.1265446. Epub 2016 Dec 2.
7
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study.奥希替尼治疗获得性 Thr790Met 突变的非小细胞肺癌患者的结局：一项基因组研究。
Lancet Respir Med. 2018 Feb;6(2):107-116. doi: 10.1016/S2213-2600(17)30480-0. Epub 2017 Dec 14.
8
Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations.奥希替尼治疗携带G719S、S768I和T790M突变的肺腺癌未成功。
Intern Med. 2018 Dec 15;57(24):3643-3645. doi: 10.2169/internalmedicine.0923-18. Epub 2018 Aug 24.
9
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.第三代表皮生长因子受体酪氨酸激酶抑制剂用于晚期非小细胞肺癌
Curr Opin Oncol. 2016 Mar;28(2):115-21. doi: 10.1097/CCO.0000000000000260.
10
NICE approves osimertinib for advanced lung cancer.英国国家卫生与临床优化研究所批准奥希替尼用于治疗晚期肺癌。
Lancet Respir Med. 2016 Dec;4(12):954. doi: 10.1016/S2213-2600(16)30368-X. Epub 2016 Nov 1.

引用本文的文献

1
Clinical Trials for Oral, Inhaled and Intravenous Drug Delivery System for Lung Cancer and Emerging Nanomedicine-Based Approaches.肺癌口服、吸入和静脉内药物输送系统的临床试验和新兴的基于纳米医学的方法。
Int J Nanomedicine. 2023 Dec 21;18:7865-7888. doi: 10.2147/IJN.S432839. eCollection 2023.
2
Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review).三代 EGFR-TKI 耐药的机制及处理策略在晚期非小细胞肺癌中的应用（综述）。
Int J Oncol. 2021 Nov;59(5). doi: 10.3892/ijo.2021.5270. Epub 2021 Sep 24.
3
Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance.
第三代EGFR TKI耐药中全球蛋白质组和磷酸化蛋白质组的改变揭示了规避耐药的药物靶点。
Cancer Res. 2021 Jun 1;81(11):3051-3066. doi: 10.1158/0008-5472.CAN-20-2435. Epub 2021 Mar 16.
4
Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors.表皮生长因子受体酪氨酸激酶抑制剂的发展以及应对第三代表皮生长因子受体酪氨酸激酶抑制剂奥希替尼耐药的策略：传统方法与免疫检查点抑制剂
Front Oncol. 2020 Dec 18;10:602762. doi: 10.3389/fonc.2020.602762. eCollection 2020.
5
Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program.奥希替尼用于既往接受过治疗的晚期表皮生长因子受体（EGFR）T790M 突变阳性非小细胞肺癌（NSCLC）患者：来自扩大可及项目的耐受性和诊断方法
Oncol Ther. 2018 Jun;6(1):45-58. doi: 10.1007/s40487-018-0061-y. Epub 2018 May 25.
6
Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer.非小细胞肺癌中循环肿瘤DNA、靶向治疗和免疫治疗的前沿进展
Transl Lung Cancer Res. 2020 Feb;9(1):111-138. doi: 10.21037/tlcr.2020.01.09.
7
Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations.TAS-121（第三代表皮生长因子受体 [EGFR] 酪氨酸激酶抑制剂）治疗携带 EGFR 突变的非小细胞肺癌患者的 I 期研究。
Invest New Drugs. 2019 Dec;37(6):1207-1217. doi: 10.1007/s10637-019-00732-4. Epub 2019 Feb 21.
8
Preclinical studies reveal that LSD1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations.临床前研究表明，LSD1 抑制可导致肺腺癌肿瘤生长停滞，而与驱动突变无关。
Mol Oncol. 2018 Nov;12(11):1965-1979. doi: 10.1002/1878-0261.12382. Epub 2018 Oct 13.
9
Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers.表皮生长因子受体（EGFR）抑制剂和放疗在 EGFR 突变型肺癌脑转移治疗中的作用。
Oncologist. 2018 Sep;23(9):1054-1062. doi: 10.1634/theoncologist.2017-0557. Epub 2018 Apr 27.
10
[Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer].[非小细胞肺癌对第三代表皮生长因子受体酪氨酸激酶抑制剂的耐药机制]
Zhongguo Fei Ai Za Zhi. 2018 Feb 20;21(2):110-115. doi: 10.3779/j.issn.1009-3419.2018.02.02.